Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors
Journal for ImmunoTherapy of Cancer · 2025
DOI: 10.1136/jitc-2024-010945 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Melanie Grandits und 17 weiteren Autor:innen. Beteiligte Einrichtung: St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King's College London, London, UK. Hauptthemen laut MEDLINE: Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK City of London Centre, Worldwide Cancer Research, Breast Cancer Now.
Abstract (Originalsprache)
Background
Anti-human epidermal growth factor receptor 2 (HER2) IgG1-based antibody therapies significantly improve cancer prognosis, yet intrinsic or acquired resistance to fragment antigen-binding (Fab)-mediated direct effects commonly occurs. Most resistant tumors retain antigen expression and therefore remain potentially targetable with anti-HER2 therapies that promote immune-mediated responses. Tumor-antigen-specific IgE class antibodies can mediate powerful immune cell-mediated effects against different cancers and have been shown to activate IgE Fc receptor-expressing monocytes. We previously reported the engineering of a trastuzumab-equivalent anti-HER2 IgE antibody and showed early evidence of Fc-mediated cancer cell-targeting effects. In the present study, we evaluated the anti-tumoral functions of two anti-HER2 IgEs, trastuzumab and pertuzumab IgE.
Methods
In vitro functionality of the two anti-HER2 antibodies was assessed by HER2 phosphorylation and ligand-independent viability assays, as well as basophil (RBL-SX38) degranulation, antibody-dependent cellular cytotoxicity/antibody-dependent cellular phagocytosis(ADCC/ADCP) assays and primary monocyte stimulation assays. The potential to trigger a hypersensitivity type I reaction was investigated using the basophil activation test (BAT). anti-tumoral efficacy was assessed in two humanized HER2+, trastuzumab-resistant models in vivo. Changes in the tumor microenvironment were assessed by flow cytometry or bulk RNA sequencing.
Results
We demonstrate the anti-tumoral and immunostimulatory functions of two anti-HER2 IgEs derived from variable region sequences of the clinically available trastuzumab and pertuzumab IgG1 antibodies. IgE engagement of monocytes via the Fc region induced tumor cell cytotoxicity and a pro-inflammatory shift with upregulation of immune-stimulatory CD40, CD80 and CD86, and downregulation of scavenger CD163, cell surface molecules. This was accompanied by enhanced pro-inflammatory tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β cytokine production. The absence of basophil activation by anti-HER2 IgEs ex vivo in whole blood points to potentially safe administration in humans. In two trastuzumab-resistant HER2+ tumor xenograft models in immunodeficient mice reconstituted with human immune cells, the trastuzumab-equivalent anti-HER2 IgE restricted tumor growth. Treatment was associated with enriched classical (CD14 + CD16 – ) monocyte and lower alternatively-activated (CD163 + CD206 + ) macrophage infiltration, and higher densities of activated CD4 + (CD127 lo CD25 hi ) T cells and favorable effector T cell(Teff) to regulatory T cell (Treg) ratios in tumors.
Conclusion
Collectively, anti-HER2 IgE maintains Fab-mediated antitumor activity, induces Fc-mediated effects against HER2-expressing tumor cells, and stimulates remodeling of the immune microenvironment in tumors to promote pro-inflammatory cell phenotypes which could translate to improved outcomes for patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King's College London, London, UK.
- Epsilogen Ltd, Waterfront, ARC West London, Manbre Road, Hammersmith, London, UK.
- Department of Informatics, Faculty of Natural, Mathematical and Engineering Sciences, King's College London, London, UK.
- Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
- St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King's College London, London, UK heather.bax@kcl.ac.uk.
Förderung
- Cancer Research UK City of London Centre
- Worldwide Cancer Research
- Breast Cancer Now
- Epsilogen Ltd
- British Skin Foundation
- Medical Research Council
Zitieren
APA
Grandits, M., Palhares, L. C. G. F., Osborn, G., Chauhan, J., Stoker, K., Sow, H. S., Adams, R., McCraw, A. J., Chenoweth, A., Vlasova, S., López-Abente, J., Ilieva, K. M., Birtley, J., Tsoka, S., Hardaker, E., FitzGerald, K., Karagiannis, S. N., & Bax, H. J. (2025). Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010945
Vancouver
Grandits M, Palhares LCGF, Osborn G, Chauhan J, Stoker K, Sow HS, et al. Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-010945
BibTeX
@article{Grandits2025,
author = {Grandits, Melanie and Palhares, Lais C G F and Osborn, Gabriel and Chauhan, Jitesh and Stoker, Katie and Sow, Heng Sheng and Adams, Rebecca and McCraw, Alex J and Chenoweth, Alicia and Vlasova, Sofia and López-Abente, Jacobo and Ilieva, Kristina M and Birtley, James and Tsoka, Sophia and Hardaker, Elizabeth and FitzGerald, Kevin and Karagiannis, Sophia N and Bax, Heather J},
title = {Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
doi = {10.1136/jitc-2024-010945}
}
EUVIMED